Association Between Vitamin D Receptor Gene Polymorphisms and Polycystic Ovary Syndrome Risk: A Meta-Analysis

Overview

Journal Front Physiol

Date 2019 Jan 29

PMID 30687119

Citations 6

Authors

Yu-Ming Niu

Ya-Dong Wang

Guang-Bin Jiang

Gang Bai

Hong-Bo Chai

Xue-Feng Li

Yuan-Yuan Hu

Ming Shen

Affiliations

Soon will be listed here.

Abstract

Published studies have demonstrated a closer association between vitamin D receptor (VDR) gene polymorphisms and polycystic ovary syndrome (PCOS) risk, but the results were inconsistent. We therefore performed this meta-analysis to explore the precise associations between VDR gene polymorphisms and PCOS risk. Five online electronic databases (PubMed, Embase, SCI index, CNKI and Wanfang) were searched. Odds ratios (ORs) with 95% confidence interval (CIs) were calculated to assess the association between VDR Fok I C/T (rs10735810), BsmI A/G (rs1544410), ApaI A/C (rs7975232), and TaqI T/C (rs731236) polymorphisms and PCOS risk. In addition, heterogeneity, accumulative/sensitivity analysis and publication bias were conducted to check the statistical power. Overall, 10 publications (31 independent case-control studies) involving 1,531 patients and 1,174 controls were identified. We found that the C mutation of ApaI A/C was a risk factor for PCOS (C vs. A: OR = 1.20, 95%CI = 1.06-1.35, < 0.01, = 29.7%; CC vs. AA: OR = 1.49, 95%CI = 1.17-1.91, < 0.01, = 0%; CC vs. AA+AC: OR = 1.36, 95%CI = 1.09-1.69, = 0.01, = 12.8%). Moreover, the BsmI A/G polymorphism also showed a dangerous risk for PCOS in Asian population (G vs. A: OR = 1.62, 95%CI = 1.24-2.11, < 0.01, = 0%; AG vs. AA: OR = 2.08, 95%CI = 1.26-3.20, < 0.01, = 0%; GG vs. AA: OR = 2.21, 95%CI = 1.29-3.77, < 0.01, = 0%; AG+GG vs. AA: OR = 2.12, 95%CI = 1.42-3.16, < 0.01, = 0%). In addition, no significant association of Fok I C/T, and TaqI T/C polymorphisms was observed. In summary, our meta-analysis suggested that VDR gene polymorphisms contribute to PCOS development, especially in Asian populations.

Citing Articles

Polycystic Ovarian Syndrome: A Review of Multi-omics Analyses.

Naqvi I, Bandyopadhyay A, Panda A, Hareramadas B Reprod Sci. 2025; 32(3):618-646.

PMID: 39875694 DOI: 10.1007/s43032-025-01789-8.

Vitamin D receptor (VDR) gene polymorphisms and risk for polycystic ovary syndrome and infertility: An updated systematic review and meta-analysis.

Heidarzadehpilehrood R, Hamid H, Pirhoushiaran M Metabol Open. 2025; 25:100343.

PMID: 39866289 PMC: 11764755. DOI: 10.1016/j.metop.2024.100343.

Association of Gene Polymorphisms with Polycystic Ovary Syndrome: A Meta-analysis.

Abinaya G, Iyshwarya B, Veerabathiran R Gynecol Minim Invasive Ther. 2024; 13(4):232-240.

PMID: 39660240 PMC: 11626897. DOI: 10.4103/gmit.gmit_106_23.

Vitamin D and reproductive disorders: a comprehensive review with a focus on endometriosis.

Farhangnia P, Noormohammadi M, Delbandi A Reprod Health. 2024; 21(1):61.

PMID: 38698459 PMC: 11064344. DOI: 10.1186/s12978-024-01797-y.

Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature.

Palomba S, Colombo C, Busnelli A, Caserta D, Vitale G Front Endocrinol (Lausanne). 2023; 14:1251866.

PMID: 37635968 PMC: 10453810. DOI: 10.3389/fendo.2023.1251866.

References

Jurutka P, Remus L, Whitfield G, Thompson P, Hsieh J, Zitzer H . The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol. 2000; 14(3):401-20. DOI: 10.1210/mend.14.3.0435. View

Kato S . The function of vitamin D receptor in vitamin D action. J Biochem. 2000; 127(5):717-22. DOI: 10.1093/oxfordjournals.jbchem.a022662. View

Asuncion M, Calvo R, San Millan J, Sancho J, Avila S, Escobar-Morreale H . A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85(7):2434-8. DOI: 10.1210/jcem.85.7.6682. View

Zmuda J, Cauley J, Ferrell R . Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev. 2001; 22(2):203-17. DOI: 10.1093/oxfordjournals.epirev.a018033. View

Whitfield G, Remus L, Jurutka P, Zitzer H, Oza A, Dang H . Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001; 177(1-2):145-59. DOI: 10.1016/s0303-7207(01)00406-3. View

Ogunkolade B, Boucher B, Prahl J, Bustin S, Burrin J, Noonan K . Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes. 2002; 51(7):2294-300. DOI: 10.2337/diabetes.51.7.2294. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

Hill A . THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?. Proc R Soc Med. 1965; 58:295-300. PMC: 1898525. DOI: 10.1177/003591576505800503. View

Azziz R, Woods K, Reyna R, Key T, Knochenhauer E, Yildiz B . The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89(6):2745-9. DOI: 10.1210/jc.2003-032046. View

10.

Minelli C, Thompson J, Abrams K, Thakkinstian A, Attia J . The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005; 34(6):1319-28. DOI: 10.1093/ije/dyi169. View

11.

Valdivielso J, Fernandez E . Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. 2006; 371(1-2):1-12. DOI: 10.1016/j.cca.2006.02.016. View

12.

Huedo-Medina T, Sanchez-Meca J, Marin-Martinez F, Botella J . Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006; 11(2):193-206. DOI: 10.1037/1082-989X.11.2.193. View

13.

Mahmoudi T . Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertil Steril. 2009; 92(4):1381-1383. DOI: 10.1016/j.fertnstert.2009.05.002. View

14.

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber T . Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009; 161(4):575-82. DOI: 10.1530/EJE-09-0432. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

16.

Repaci A, Gambineri A, Pasquali R . The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2010; 335(1):30-41. DOI: 10.1016/j.mce.2010.08.002. View

17.

Wehr E, Trummer O, Giuliani A, Gruber H, Pieber T, Obermayer-Pietsch B . Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011; 164(5):741-9. DOI: 10.1530/EJE-11-0134. View

18.

Haussler M, Jurutka P, Mizwicki M, Norman A . Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)₂vitamin D₃: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):543-59. DOI: 10.1016/j.beem.2011.05.010. View

19.

Lewis C, Knight J . Introduction to genetic association studies. Cold Spring Harb Protoc. 2012; 2012(3):297-306. DOI: 10.1101/pdb.top068163. View

20.

Bagheri M, Abdi Rad I, Hosseini Jazani N, Nanbakhsh F . Lack of Association of Vitamin D Receptor FokI (rs10735810) (C/T) and BsmI (rs1544410) (A/G) Genetic Variations with Polycystic Ovary Syndrome Risk: a Case-control Study from Iranian Azeri Turkish Women. Maedica (Bucur). 2013; 7(4):303-8. PMC: 3593280. View